


Sulfasalazine-d₄

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-14655S | | |
| CAS No.: | 1346606-50-5 | | |
| Molecular Formula: | C ₁₈ H ₁₀ D ₄ N ₄ O ₅ S | | |
| Molecular Weight: | 402.42 | | |
| Target: | Apoptosis; Bacterial; Autophagy; NF-κB; Ferroptosis; Antibiotic; Isotope-Labeled Compounds | | |
| Pathway: | Apoptosis; Anti-infection; Autophagy; NF-κB; Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Sulfasalazine-d ₄ is the deuterium labeled Sulfasalazine. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer[1][2][3][4]. |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Mao C, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. *Nature*. 2021;593(7860):586-590.
- [3]. Wahl C, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. *J Clin Invest*. 1998 Mar 1;101(5):1163-74.
- [4]. Sykes L, et al. Sulfasalazine augments a pro-inflammatory response in interleukin-1β-stimulated amniocytes and myocytes. *Immunology*. 2015 Dec;146(4):630-44.
- [5]. Chung WJ, et al. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. *J Neurochem*. 2009 Jul;110(1):182-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA